Li X, Wu T, Dong R, Wu X
Discov Oncol. 2025; 16(1):207.
PMID: 39969753
PMC: 11839969.
DOI: 10.1007/s12672-025-01944-2.
Hatzimanolis O, Sykes A, Cristino A
Mol Psychiatry. 2025; .
PMID: 39966624
DOI: 10.1038/s41380-025-02925-1.
Lv Q, Wang G, Hong Y, Zhu T, Qin S, Sun S
Oncol Res. 2025; 33(2):407-420.
PMID: 39866227
PMC: 11754003.
DOI: 10.32604/or.2024.047698.
Jin G, Song Y, Fang S, Yan M, Yang Z, Shao Y
J Exp Clin Cancer Res. 2025; 44(1):8.
PMID: 39773744
PMC: 11705778.
DOI: 10.1186/s13046-024-03264-9.
Schaft N, Dorrie J
Methods Mol Biol. 2024; 2883:79-107.
PMID: 39702705
DOI: 10.1007/978-1-0716-4290-0_4.
Circular RNA CDR1as/ciRS-7- a novel biomarker in solid tumors.
Zhang Y, Xiong C, Jiang Z, Wang X, Ji J, Pan Y
Front Oncol. 2024; 14:1468363.
PMID: 39678511
PMC: 11638042.
DOI: 10.3389/fonc.2024.1468363.
FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner.
Gao H, Shi L, Liu J, Zhao Y, Du F, He Y
Mol Cell Biochem. 2024; .
PMID: 39630361
DOI: 10.1007/s11010-024-05170-2.
Circ_0001944 Targets the miR-1292-5p/FBLN2 Axis to Facilitate Sorafenib Resistance in Hepatocellular Carcinoma by Impeding Ferroptosis.
Jing F, Shi Y, Jiang D, Li X, Sun J, Guo Q
Immunotargets Ther. 2024; 13:643-659.
PMID: 39624827
PMC: 11611519.
DOI: 10.2147/ITT.S463556.
Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma.
Li G, Wu T, Li H, Wei C, Sun Y, Gao P
J Transl Med. 2024; 22(1):966.
PMID: 39449143
PMC: 11515383.
DOI: 10.1186/s12967-024-05732-4.
Feedback loop LINC00511-YTHDF2-SOX2 regulatory network drives cholangiocarcinoma progression and stemness.
Guan C, Zou X, Gao X, Liu S, Gao J, Shi W
MedComm (2020). 2024; 5(11):e743.
PMID: 39445001
PMC: 11496568.
DOI: 10.1002/mco2.743.
Unveiling ferroptosis: a new frontier in skin disease research.
Wang K, Lin Y, Zhou D, Li P, Zhao X, Han Z
Front Immunol. 2024; 15:1485523.
PMID: 39430757
PMC: 11486644.
DOI: 10.3389/fimmu.2024.1485523.
Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response.
Fischer K, Tiwari S, Thier B, Qiu L, Lin T, Paschen A
Front Mol Biosci. 2024; 11:1471100.
PMID: 39398277
PMC: 11466874.
DOI: 10.3389/fmolb.2024.1471100.
Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy in a prospective Chinese cohort.
Yuan C, Xu Y, Zhou L, Peng J, Sha R, Lin Y
Eur J Med Res. 2024; 29(1):454.
PMID: 39261936
PMC: 11389417.
DOI: 10.1186/s40001-024-02015-y.
mA modification enhances the stability of promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle.
Pan Y, Feng H, Zhou J, Zhang W, Liu Y, Zheng J
Int J Biol Sci. 2024; 20(11):4209-4221.
PMID: 39247830
PMC: 11379066.
DOI: 10.7150/ijbs.98535.
Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.
Racca L, Liuzzi E, Comparato S, Giordano G, Pignochino Y
Int J Mol Sci. 2024; 25(16).
PMID: 39201617
PMC: 11354327.
DOI: 10.3390/ijms25168934.
Gene Expression Profile Identifies LncRNA AL355974.3 As a Potential Glioma Biomarker.
Lu H, Chen Y, Yu Y, Liao X, Liang H, Liang L
Curr Med Sci. 2024; 44(5):1047-1057.
PMID: 39145837
DOI: 10.1007/s11596-024-2899-6.
Circular RNA in cancer.
Conn V, Chinnaiyan A, Conn S
Nat Rev Cancer. 2024; 24(9):597-613.
PMID: 39075222
DOI: 10.1038/s41568-024-00721-7.
Readers of RNA Modification in Cancer and Their Anticancer Inhibitors.
Li F, Li W
Biomolecules. 2024; 14(7).
PMID: 39062595
PMC: 11275166.
DOI: 10.3390/biom14070881.
Coding, or non-coding, that is the question.
Poliseno L, Lanza M, Pandolfi P
Cell Res. 2024; 34(9):609-629.
PMID: 39054345
PMC: 11369213.
DOI: 10.1038/s41422-024-00975-8.
Noncoding RNAs in tumorigenesis and tumor therapy.
Zhu P, Liu B, Fan Z
Fundam Res. 2024; 3(5):692-706.
PMID: 38933287
PMC: 11197782.
DOI: 10.1016/j.fmre.2023.05.014.